Quantum BioPharma Submits MS Drug Candidate to UK’s ILAP Program
Quantum BioPharma Ltd. (NASDAQ: QNTM) has taken a pivotal step in the development of its multiple sclerosis (MS) treatment by submitting its drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program. This submission underscores the company’s commitment to leveraging strategic regulatory pathways to expedite the clinical advancement and patient […]